Adamis Pharmaceuticals

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

Tempol Reduced Lung Inflammation After High Dose Challenge Tempol Reduced Lung Inflammation After High Dose Challenge

Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level. The batches in the table below are being recalled due to the potential clogging of the needle preventing the dispensing of epinephrine. US WorldMeds (USWM) exclusively markets and distributes SYMJEPI in the United States, under license from Adamis, the NDA holder. USWM will handle the entire recall process for Adamis, with Adamis oversight. SYMJEPI is manufactured and tested for Adamis by Catalent Belgium S.A.

Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022.

Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board

Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to continue Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to continue

Adamis Pharmaceuticals' Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today announced that the compensation committee of the board of directors and the company's independent directors approved the grant of stock options on February 15, 2022, to purchase an aggregate of 130,000 shares of common stock to two non-officer employees who were not previously employees of the company. The stock options were granted as material inducements to acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term and have an exercise price of $0.62 per share, the closing price of the company's common stock on February 15, 2022, the grant date. The options vest over a three year period, with the option vesting and becoming exercisable with respect to one-sixth of the shares subject to the option on the six month anniversary of the date of first employment and the remainder vesting in equal monthly installments over a 36 month period from the date of first employment, provided the employee continues to provide service to the company through the applicable vesting dates. The stock options were granted outside of the company's 2020 equity incentive plan.

Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company's ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now examine clinical and safety data from the first 50 subjects as part of the first interim analysis.

Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals is moving TEMPOL forward against COVID-19. The FDA recently announced that they submitted a Fast Track application for TEMPOL. TEMPOL has the potential to both prevent disease progression and reduce replication. I match TEMPOL up against contemporary COVID-19 products.

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Bone Biologics Corp

Ocugen, Inc.

These penny stocks climbed today, here's why The post 3 Penny Stocks to Watch With the Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch With the Stock Market Down Today

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19. Tempol is currently being studied in a Phase 2/3 clinical trial in adult patients with confirmed COVID-19 infection. Tempol has been shown to have antiviral, anti-inflammatory, and antioxidant activity. Although recent oral antiviral drugs have been approved by the FDA, the Company believes that Tempol would provide an unmet medical need because of its unique mechanism of action and safety profile.

Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?

Adamis Pharmaceuticals has two FDA-approved products and a potential blockbuster drug in TEMPOL. However, the company has a long history of blunders that have devastated the share price. I believe the company has a chance to make 2022 a turnaround year, but it is going to require making deals and not excuses to get investors reinvigorated about ADMP.

Adamis Pharmaceuticals: It's Now Or Never

Agile Therapeutics

Borqs Technologies

Check these Under $1 penny stocks out for your watchlist The post Top Penny Stocks For Your Under $1 List Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks For Your Under $1 List Right Now

Drug overdoses are the leading cause of death for those under age 50 Drug overdoses are the leading cause of death for those under age 50

Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™

SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“NASDAQ”) notifying the company that based on the company's filing of its Quarterly Reports on Form 10-Q for the periods ended March 31, 2021, June 30, 2021 and September 30, 2021, the company has regained compliance with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission, and that the matter is now closed.

Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements

The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) fell by over 15% pre-market today. This is why it happened.

Adamis Pharmaceuticals (ADMP) Stock: Why The Price Dropped Today

Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q3 2021 Result - Earnings Call Transcript

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET

Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, November 22, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the first nine months of 2021, as well as provide a business update. The Company's press release concerning its financial results will be available after 1 p.m. Pacific Time on November 22, 2021 and on its website at www.adamispharmaceuticals.com, and the company also expects to file its quarterly reports on Form 10-Q for the quarters ended March 31, 2021, June 30, 2021 and September 30, 2021 on that date.

Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update

Denison Mines

If you're making a penny stocks watchlist right now, check these three small-caps out The post Top Penny Stocks to Watch Making Big Moves Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch Making Big Moves Right Now

Adamis Pharmaceuticals (ADMP) stock is getting a major boost on Monday thanks to a response from the U.S. Food and Drug Administration. The post ADMP Stock: The FDA News That Has Penny Stock Adamis Pharmaceuticals Rocketing Today appeared first on InvestorPlace.

ADMP Stock: The FDA News That Has Penny Stock Adamis Pharmaceuticals Rocketing Today

Farmmi

ION Geophysical

Lipocine

Progenity

A jump in penny stock prices has retail traders cashing out on big gains. The post Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others

Shares of Adamis Pharmaceuticals Corp. ADMP, +2.73% soared 20.4% on massive volume toward an eight-month high in premarket trading Monday, after the biopharmaceutical company said Zimhi, it's high-dose naloxone injection for the treatment for opioid overdose, has been approved by the Food and Drug Administration. Trading volume spiked to 32.8 million shares, enough to make the stock the most actively traded ahead of the open, and compared with the full-day average of about 2.0 million shares.

Adamis Pharmaceuticals stock rockets on heavy volume after opioid overdose treatment gets FDA approval

The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) increased by over 35% pre-market today. This is why it happened.

ADMP Stock: Why The Price Substantially Increased Today

New High-Dose Naloxone Product for the Treatment of Opioid Overdose New High-Dose Naloxone Product for the Treatment of Opioid Overdose

Adamis Receives FDA Approval for ZIMHI

Appointment of New Director with Significant Experience in Drug Development, Licensing and Commercialization Appointment of New Director with Significant Experience in Drug Development, Licensing and Commercialization

News for Adamis Pharmaceuticals Stock (ADMP)